Skip to main content
Tara Frenkl, MD, Urology, Philadelphia, PA, Hospital of the University of Pennsylvania

TaraLeeFrenklMD

Urology Philadelphia, PA

Physician

Dr. Frenkl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Frenkl's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd
    West Pavilion, 3rd Floor
    Philadelphia, PA 19104
    Phone+1 215-662-2891
    Fax+1 215-662-6734
  • Is this information wrong?

Education & Training

  • Brown University
    Brown UniversityResidency, Urology, 1999 - 2003
  • Brown University
    Brown UniversityResidency, Surgery, 1998 - 1999
  • Duke University Hospital
    Duke University HospitalInternship, Transitional Year, 1996 - 1997
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 1996

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2006 - 2024
  • OH State Medical License
    OH State Medical License 2003 - 2007
  • NJ State Medical License
    NJ State Medical License 1992 - 2007
  • NC State Medical License
    NC State Medical License 1997 - 1998
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

Press Mentions

  • Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate Cancer
    Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
  • Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate Cancer
    Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
  • Bayer : New Data Presented at ASCO GU Confirm Survival Benefits and Favorable Safety Profile of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
    Bayer : New Data Presented at ASCO GU Confirm Survival Benefits and Favorable Safety Profile of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate CancerFebruary 20th, 2023

Hospital Affiliations